Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03603405 · ClinicalTrials.gov registry record · Phase 1
HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM
A Phase 1 study of Glioblastoma and Anaplastic Astrocytoma, sponsored by The Methodist Hospital Research Institute.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 62
- Enrollment target
- 1
- Study location
NCT03603405: Recruiting Phase 1 study of Glioblastoma and Anaplastic Astrocytoma, sponsored by The Methodist Hospital Research Institute.
NCT03603405 is a Phase 1 study of Glioblastoma and Anaplastic Astrocytoma that is actively recruiting participants, run by The Methodist Hospital Research Institute. The registered enrollment target is 62 participants, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (43% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03603405, a Phase 1 study of Glioblastoma and Anaplastic Astrocytoma, is actively recruiting participants, sponsored by The Methodist Hospital Research Institute.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 62 participants
- Enrollment target
- 1
- Study location
Study Summary
Study to assess the safety and efficacy of HSV-tk (gene therapy), valacyclovir, radiotherapy and chemotherapy in newly diagnosed glioblastoma multiforme (GBM) or anaplastic astrocytoma (AA).
Primary Outcome
The overall survival rate of patients with Anaplastic Astrocytoma and Glioblastoma in months will be assessed up to 5 years from study drug administration.
Conditions Studied
Interventions
- DRUG ADV/HSV-tk (gene therapy)
Study Locations (1)
Texas
- Houston Methodist Neurological Institute - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2018-02-28 |
| Est. Completion | 2025-12-31 |
| Phase | Phase 1 |
What NCT03603405 shows while recruiting
NCT03603405 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 62 participants, a relatively small participant target, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (43% lower).
The record links to 2 conditions, with Glioblastoma appearing as the primary indexed condition, and to 1 intervention - of which ADV/HSV-tk (gene therapy) is the first listed.
NCT03603405 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT03603405 about?
NCT03603405 is a clinical study titled "HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM". Study to assess the safety and efficacy of HSV-tk (gene therapy), valacyclovir, radiotherapy and chemotherapy in newly diagnosed glioblastoma multiforme (GBM) or anaplastic astrocytoma (AA).
What is the current status of trial NCT03603405?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 62 participants. The study started on 2018-02-28. Estimated completion is 2025-12-31.
What conditions does trial NCT03603405 study?
This clinical trial studies the following conditions: Glioblastoma, Anaplastic Astrocytoma.
What interventions are being tested in trial NCT03603405?
The interventions under investigation include: ADV/HSV-tk (gene therapy) (DRUG).
Who is sponsoring clinical trial NCT03603405?
This trial is sponsored by The Methodist Hospital Research Institute, which has 126 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03603405 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03603405's enrollment target sits among peer trials
62 71st of 199 higher than 127 of 199 other Glioblastoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glioblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
RECRUITING · Phase 1
-
A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma
RECRUITING · Phase 1
-
CARv3-TEAM-E T Cells in Glioblastoma
RECRUITING · Phase 1
-
CUE-102 in Recurrent Glioblastoma
RECRUITING · Phase 1
-
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
RECRUITING · Phase 1
-
Laser Interstitial Thermal Therapy (LITT) and Lomustine (CCNU) for Recurrent Glioblastoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03231150 · 62 participants · NA
Plantar Fasciitis Randomized Clinical Control Trial
- NCT03458676 · 62 participants · NA
Radiologic Pathologic Correlation of Advanced MR Imaging to Guide the Biopsy of Cerebral Malignancies
- NCT03596086 · 62 participants · Phase 1
HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM
- NCT03904498 · 62 participants · Phase 2
COMT Inhibition Among Individuals With Comorbid AUD/ADHD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI